18 recruiting, 14 completed, 5 not yet recruiting, 5 unknown. 44 Phase 2, 3 Phase 1, 2 Phase 3.
Follow Major Depressive Disorder (MDD): new trials by email Literature Review of Major Depressive Disorder (MDD) trials Research Report on Major Depressive Disorder (MDD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Thiamine (Vitamin B1) for Depression in Children and Adolescents thiamine hydrochloride 100 mg - Major Depressive Disorder (MDD), Thiamine | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2026-10-01 | 2026-08-28 |
| Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder Pregnenolone, Placebo - Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD) | Phase 2 | Not yet recruiting | Sherwood Brown, MD, PhD | 100 | 2026-10-01 | 2026-08-24 |
| Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression Sertraline - Major Depressive Disorder (MDD), Probiotic Intervention | Phase 2 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 120 | 2026-10-01 | 2026-06-12 |
| A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder ALKS 7290 Dose, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Alkermes, Inc. | 180 | 2026-10-01 | 2026-10-28 |
| Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression Ketamine (0.5 mg/kg), Behavioural Activation Therapy - Treatment Resistant Depression, Major Depressive Disorder (MDD) | Phase 2 / Phase 3 | Not yet recruiting | The Royal's Institute of Mental Health Research | 60 | 2026-09-01 | 2026-09-03 |
| Precision Depression Adalimumab Trial Adalimumab Biosimilars Injection, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Daniel Moriarity | 60 | 2026-09-01 | 2026-09-29 |
| Pregnenolone for Cannabis Use Disorder and Depression Pregnenolone - Cannabis Use Disorder, Major Depressive Disorder (MDD) | Phase 1 / Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 20 | 2026-09-01 | 2026-07-06 |
| Inhaled DMT for Major Depressive Disorder N,N-Dimethyltryptamine (15 mg + 60 mg), N,N-Dimethyltryptamine (1 mg + 4 mg) - MDD, Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Universidade Federal do Rio Grande do Norte | 140 | 2026-08-01 | 2026-07-13 |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT) - Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder | Phase 2 | Recruiting | Joshua Rosenblat | 120 | 2026-07-16 | 2026-07-29 |
| A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) TNX-102 SL, Placebo sublingual tablet - Major Depressive Episode (MDE), Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Tonix Pharmaceuticals, Inc. | 360 | 2026-06-25 | 2026-10-30 |
| Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression Sertraline combined with Lactobacillus crispatus, Sertraline combined with placebo - Major Depressive Disorder (MDD), Probiotic Intervention | Phase 2 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 60 | 2026-06-11 | 2026-06-15 |
| Cannabidiol Oil for Treatment-Resistant Major Depression Full-spectrum CBD oil 100 mg/mL, Placebo oil (MCT oil) - Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD) | Phase 1 / Phase 2 | Recruiting | Universidade do Sul de Santa Catarina | 120 | 2026-06-01 | 2026-07-10 |
| A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression DT-101, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Draig Therapeutics Ltd | 118 | 2026-05-14 | 2026-10-14 |
| Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder Psilocybin 25 mg, Placebo - Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD) | Phase 2 | Recruiting | Centre for Addiction and Mental Health | 30 | 2026-03-23 | 2026-10-26 |
| A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression Treatment with Ketamine Hydrochloride Prolonged-Release Tablets - Major Depressive Disorder (MDD) | Phase 2 | Active not recruiting | Daniel Lindqvist | 12 | 2026-03-13 | 2026-06-18 |
| Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder SPN-821 2400 mg, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Supernus Pharmaceuticals, Inc. | 230 | 2026-01-19 | 2026-10-28 |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression DT-101, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Draig Therapeutics Ltd | 300 | 2025-12-16 | 2026-10-08 |
| Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL) Ketamine, Cognitive Behavioural Therapy - Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD) | Phase 1 / Phase 2 | Not yet recruiting | South West Sydney Local Health District | 20 | 2025-12-10 | 2025-11-25 |
| Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder Dextromethorphan-Bupropion - Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Roger McIntyre | 30 | 2025-11-21 | 2026-04-13 |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response ACP-211, Placebo - Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant | Phase 2 | Recruiting | ACADIA Pharmaceuticals Inc. | 153 | 2025-11-14 | 2026-10-05 |
Showing 20 of 44. Sign in to see all of them.
Depressive Disorder, Major (44) · Depression (12) · Depressive Disorder, Treatment-Resistant (5) · Mood Disorders (4) · Alcoholism (3) · Anxiety Disorders (3) · Depressive Disorder (3) · Suicidal Ideation (3) · Amyotrophic Lateral Sclerosis (1) · Bipolar Disorder (1) · Borderline Personality Disorder (1) · Disorders of Excessive Somnolence (1) · Inflammation (1) · Multiple Sclerosis (1) · Parkinson Disease, Familial, Type 1 (1)
Mental Disorders (44) · Depressive Disorder (41) · Mood Disorders (40) · Behavior (15) · Behavioral Symptoms (15) · Alcohol-Related Disorders (3) · Chemically-Induced Disorders (3) · Self-Injurious Behavior (3) · Nervous System Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Substance-Related Disorders (2) · Suicide (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1)
Ketamine (5) · Cognitive Behavioral Therapy (2) · Midazolam (2) · Pregnenolone (2) · ammoxetine (2) · Duloxetine Hydrochloride (1) · GW117 (1) · N,N-Dimethyltryptamine (1) · Orexin Receptor Antagonists (1) · Psilocybin (1) · Psychotherapy (1) · RX-10100 (1) · Sertraline (1) · Therapeutics (1) · Thiamine (1)
GlaxoSmithKline (3) · Shanghai Mental Health Center (3) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Draig Therapeutics Ltd (2) · First Affiliated Hospital of Chongqing Medical University (2) · Seaport Therapeutics (2) · The Royal's Institute of Mental Health Research (2) · ACADIA Pharmaceuticals Inc. (1) · Alkermes, Inc. (1) · Baylor College of Medicine (1) · Beijing Greatway Pharmaceutical Technology Co.,Ltd. (1) · Centre for Addiction and Mental Health (1) · Chase Therapeutics Corporation (1) · Chengdu Kanghong Pharmaceutical Group Co., Ltd. (1) · Daniel Lindqvist (1)
United States (21) · China (9) · Canada (6) · Czechia (4) · Bulgaria (3) · Poland (3) · Brazil (2) · Germany (2) · Hungary (2) · Slovakia (2) · Australia (1) · Denmark (1) · Japan (1) · Netherlands (1) · Portugal (1)
David Walling, Ph.D. (2) · Huafang LI, MD PhD (2) · Jennifer Phillips, PhD (2) · Christine Peterson, PhD (1) · Dan V Iosifescu, MD,M.Sc. (1) · Daniel Lindqvist, PhD, MD (1) · Daniel P. Moriarity, PhD (1) · E. Sherwood Brown (1) · Huang Yanli, MD (1) · Jeanne Talbot, MD, PhD (1) · Joshua D. Rosenblat, MD, MSc (1) · Li Huafang, Ph.D (1)
PMID 22203317, PMID 23982301, PMID 25271445, PMID 27089159, PMID 29137655, PMID 30368163, PMID 35963181, PMID 40982284, PMID 41425080, PMID 42289374
2025 (3), 1UG3DA066242-01 (1), 2023 (1), R01AA033156 (1), R34MH094535 (1)